MEDMON 2021
Tajikistan, 2021
Get MicrodataIdentification
TJK_2021_MEDMON_v01
MEDMON 2021
MEDMON 2021
| Name | Country code |
|---|---|
| Tajikistan | TJK |
MEDMON
This is the 2021 MEDMON conducted by Tajikistan. This report presents results of a facility-based survey conducted in April-May 2021 on the availability and prices of essential medicines in community pharmacies in Tajikistan using MedMon. Medicines were selected for the survey based on their inclusion in the national essential medicines list and the Sustainable Development Goal (SDG) 3.b.3. Core Tracer Medicines List. The SDG Core Tracer Medicines List is a list of tracer essential medicines for acute and chronic, communicable and noncommunicable diseases in the primary health care setting proposed by WHO to monitor progress against SDG indicator 3.b.3: “Proportion of health facilities that have a core set of relevant essential medicines available and affordable on a sustainable basis”. Where multiple strengths or dosage forms of certain medicines were applicable for inclusion, expert reviews identified the most frequently prescribed strength and dosage form for inclusion in the survey. The availability and price of core medicines (specific international non-proprietary name (INN)–strength–dosage form combinations) were recorded at all included facilities. To ensure that variations in procurement, prescribing and dispensing practices were considered, the availability of alternative strengths and dosage forms, and therapeutic alternatives was also recorded. For the pricing survey of core medicines, a complete list of brands registered in the country was prepared based on the national medicines registry.
Access to medicines, vaccines and health products is an essential component of universal health coverage. It represents one of the building blocks of a well-functioning health system and is an essential determinant of better health outcomes at individual and population levels. To enable regular monitoring of patient-level indicators of access, in 2016, WHO launched the MedMon mobile application for monitoring the price and availability of essential medicines and health products. This study presents the results of a facility-based survey conducted in April–May 2021 on the availability and prices of essential medicines in community pharmacies in Tajikistan using MedMon. The cross-sectional survey was conducted by the Tajikistan Ministry of Health, with support from WHO Tajikistan, WHO Regional Office for Europe and WHO Headquarters. The objectives of the survey were to obtain updated data on the availability and prices of selected essential medicines of national importance to assess the population’s access to such medicines in the outpatient setting, and to build capacity in the country to regularly monitor the prices and availability of such medicines.
Facility survey data [fsd]
Health facilities
Version
Public-use dataset
Scope
The MedMon survey collected comprehensive data, including unique identifiers for each surveyed facility, the region and type of facility, therapeutic categories, and specifics like dosage strength, form, and INN. It also recorded medicine availability, stock out duration, next expected delivery, pack and unit prices, the number of brands, and WHO AWaRe classification for antibiotics. Additional variables included whether facilities had special licenses to sell psychotropic medicines, identifiers for data collectors, and the survey date. Data analysis focused on the availability of medicines by category and region, stock outs, and pricing metrics, including the minimum, median, and maximum prices of core medicines, the number of unique brands, and price ratios across regions.
| Topic | Vocabulary |
|---|---|
| MEDMON | Survey |
Coverage
Tajikistan's five regions, including the capital city of Dushanbe, Gorno-Badakhshan Autonomous Oblast (GBAO), Sughd, Khatlon, and Districts of Republican Subordination (RRS).
Producers and sponsors
| Name |
|---|
| Ministry of Health |
| Name |
|---|
| Ministry of Health, Welfare and Sport of the Netherlands |
| German Collaboration Programme |
| Name | Role |
|---|---|
| Ministry of Health, Tajikistan | Implementing Agency |
| WHO Country Office, Tajikistan | Implementing Agency |
| WHO Region Office for Europe | Implementing Agency |
| WHO Headquarters | Implementing Agency |
Sampling
The MedMon 2021 survey in Tajikistan employed a stratified sampling strategy, selecting 103 private pharmacies across four regions and the capital city based on the national list of registered pharmacies. This selection ensured a 95% confidence level with a 10% margin of error. Only private pharmacies were included due to the limited number of public pharmacies. The survey covered a range of essential medicines, categorized by therapeutic areas, and data were collected using the MedMon mobile application. Data collectors, primarily pharmaceutical inspectors, recorded the availability and prices of these medicines, noting stockouts and expected delivery dates for unavailable items.
Data collection
| Start | End |
|---|---|
| 2021-04 | 2021-05 |
- Face-to-face [f2f]
| Name |
|---|
| Inspectors of the pharmaceutical regulator |
The MedMon survey includes comprehensive data, including unique identifiers for each surveyed facility, the region and type of facility, therapeutic categories and specific medicine details, as trade names, INN, dosage strength, and dosage form. It also recorded medicine availability, availability of therapeutic alternatives, stock out duration, next expected delivery, pack and unit prices, and the number of brands available at the time of survey. Medicines were selected based on their inclusion in the national essential medicines list and the Sustainable Development Goal (SDG) 3.b.3. Core Tracer Medicines List. Additional variables included whether facilities had special licenses to sell psychotropic medicines and facility visit date. Data analysis included the availability of medicines by category, including by WHO AWaRe antibiotic classification, and availability of medicines by region, stock outs reports, and pricing metrics, including the minimum, median, and maximum prices of core medicines, the number of unique brands, and price ratios across regions.
Data Access
| Name | Affiliation | |
|---|---|---|
| NCD Surveillance Team | World Health Organization | ncdmonitoring@who.int |
The user undertakes:
(1) to acknowledge the data source.
(2) to share any planned publications with WHO prior to publication.
(3) to offer co-authorship of any reports or publications using the survey results to the coordinator of the survey.
(4) to use the data for non-commercial, not-for-profit public health purposes only.
Publications based on MEDMON data should cite the survey report (if available) and acknowledge the data source in the following manner:
"This paper uses data from the [country] [year] MEDMON survey, implemented by [implementing agency] with the support of the World Health Organization."
Disclaimer and copyrights
The data is being distributed without warranty of any kind. The responsibility for the use of the data lies with the user. In no event shall the World Health Organization be liable for damages arising from its use.
Contacts
| Name | Affiliation | |
|---|---|---|
| NCD Surveillance Team | World Health Organization | ncdmonitoring@who.int |
| Yejin Lee | World Health Organization | leeyej@who.int |
| Swathi Iyengar | World Health Organization | iyengarswa@who.int |
Metadata production
DDI_TJK_2021_MEDMON_v01
| Name | Affiliation | Role |
|---|---|---|
| Yejin Lee | World Heatlh Organization | Documentation and management of study metadata |
2021
Metadata version
Version 1.0 (July 2024).